CSIMarket Company Name, Ticker, Competitors, else..
 
Shuttle Pharmaceuticals Holdings Inc   (NASDAQ: SHPH)
Other Ticker:  
 
 
Price: $0.8400 $-0.04 -4.621%
Day's High: $0.89 Week Perf: -6.66 %
Day's Low: $ 0.83 30 Day Perf: 23.53 %
Volume (M): 53 52 Wk High: $ 3.30
Volume (M$): $ 44 52 Wk Avg: $0.78
Open: $0.89 52 Wk Low: $0.29



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 2
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Shuttle Pharmaceuticals Holdings Inc
Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company that specializes in the research, development, manufacturing, and distribution of drugs and medical products. The company focuses on developing innovative solutions to address various healthcare challenges. They have a diverse portfolio of products targeting different therapeutic areas, including cardiovascular health, respiratory disorders, infectious diseases, and more. Shuttle Pharmaceuticals aims to improve the quality of life for patients and provide effective treatments for various medical conditions. They also collaborate with other healthcare organizations and invest in research and development to bring new and advanced medications to the market.


   Company Address: 401 Professional Drive Gaithersburg 20879 MD
   Company Phone Number: 403-4212   Stock Exchange / Ticker: NASDAQ SHPH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
FBIO   -4.83%    
NRIX        0.68% 
RYTM   -0.64%    
SPRO   -4.11%    
SUPN        0.45% 
YMAB   -5.23%    
• View Complete Report
   



Contract

Hope and Hurdles Shuttle Pharmaceuticals Partners with UCSF Amidst Stock Challenges,

Published Thu, Dec 19 2024 2:00 PM UTC

Shuttle Pharmaceuticals: A New Alliance in Cancer Research Amidst Market Challenges In a significant development for both Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) and the broader field of oncology, the company recently announced a sponsored research agreement with the University of California, San Francisco (UCSF) to advance its prostate-specific membrane antige...
Clinical Study

Expansion of Ropidoxuridine Phase 2 Clinical Trial A Promising Step Toward Enhanced Glioblastoma Treatment

Published Tue, Nov 26 2024 2:00 PM UTC

Abstract: Shuttle Pharmaceuticals Holdings, Inc. has announced the expansion of its Phase 2 clinical trial evaluating the efficacy of Ropidoxuridine for patients with glioblastoma. With patient enrollment now active at the UVA Cancer Center, this initiative marks a significant stride in the quest for improved radiation therapy outcomes. The study, conducted across six promin...
Management Announcement

Shuttle Pharmaceuticals Reports Financial Struggles Amid Focus on Cancer Treatments

Published Wed, Nov 13 2024 10:00 PM UTC

In a recent corporate update, Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) revealed a challenging financial landscape as it navigates the complexities of the oncology market. The Gaithersburg, Maryland-based company, known for its commitment to enhancing outcomes for cancer patients undergoing radiation therapy, reported a notable decline in its stock value and sign...
Stock Market Announcement

Shuttle Pharmaceuticals: Strategic Financing Amid Promising Clinical Advancements

Published Wed, Oct 30 2024 1:06 AM UTC

On October 29, 2024, Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a Maryland-based specialty pharmaceutical company dedicated to enhancing outcomes for cancer patients undergoing radiation therapy, announced the pricing of a public offering that can potentially advance its funding capabilities and clinical objectives. The company successfully priced up to 2,950,820...
Management Announcement

Shuttle Pharma Pays Off Senior Secured Convertible Note

Published Tue, Oct 29 2024 8:05 PM UTC

Shuttle Pharmaceuticals Advances Strategic Goals through Debt Payoff and New Public OfferingIn a notable demonstration of fiscal responsibility and strategic growth, Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a Maryland-based specialty pharmaceutical company dedicated to improving outcomes for cancer patients undergoing radiation therapy, has recently completed ...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com